Valproic acid increases SMN levels in spinal muscular atrophy patient cells-Reference-Cited by-同舟云学术

Valproic acid increases SMN levels in spinal muscular atrophy patient cells

Published:2003-10-23 Issue:5 Volume:54 Page:647-654
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Sumner Charlotte J.,Huynh Thanh N.,Markowitz Jennifer A.,Perhac J. Stephen,Hill Brenna,Coovert Daniel D.,Schussler Kristie,Chen Xiaocun,Jarecki Jill,Burghes Arthur H. M.,Taylor J. Paul,Fischbeck Kenneth H.

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference37 articles.

1. The Neurobiology of Childhood Spinal Muscular Atrophy

2. Identification and characterization of a spinal muscular atrophy-determining gene

3. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy

4. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2

5. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN

Cited by 260 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges;Genes;2024-07-30

2. Insights into spinal muscular atrophy from molecular biomarkers;Neural Regeneration Research;2024-06-26

3. Spinal Muscular Atrophy;Pediatric Clinics of North America;2023-10

4. Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment;International Journal of Molecular Sciences;2023-07-26

5. Evaluation of the orally bioavailable 4-phenylbutyrate-tethered trichostatin A analogue AR42 in models of spinal muscular atrophy;Scientific Reports;2023-06-26